![Understanding Gleason system evolution for accurate prostrate diagnosis and treatment, summary by María Natalia Gandur Quiroga](https://oncodaily.com/pub/uploads/2023/09/9A5CEADA-D111-4282-B8A4-4662ED309C0A-e1709923519309.png)
Understanding Gleason system evolution for accurate prostrate diagnosis and treatment, summary by María Natalia Gandur Quiroga
María Natalia Gandur Quiroga shared a recent article by Alessandro Crestani on X, adding:
“Gleason system evolution: Fundamental for accurate prostate cancer diagnosis and prognosis, Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran Carmine Franzese, Gianluca Giannarini, Alessandro Crestani, and Eamonn T. Rogers Rodolfo Montironi.
GG1: Despite a favorable prognosis (e.g., no lymph node metastases in over 14,000 cases), it remains classified as cancer due to invasive characteristics and molecular similarities with higher grades.
Cribriform patterns and intraductal carcinoma (IDC-P): Strongly linked to poorer outcomes, aggressive behavior, and should be carefully considered in treatment decisions.
Molecular testing: Increasingly important, distinguishing GG4 and GG5 tumors, aiding in risk stratification and tailored therapies. Prognostic heterogeneity within GG4 and GG5: Highlights the need for nuanced grading to guide clinical decisions accurately.
Takeaway: Direct interaction with patients is crucial, helping them understand pathology reports and encouraging informed discussions with their healthcare providers.”
Patients ask and pathologists answer: ten questions around prostate cancer grading
Authors: Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Carmine Franzese, Gianluca Giannarini, Alessandro Crestani, Eamonn T. Rogers, and Rodolfo Montironi.